Zejula Cuts Tumor Burden in Significant Proportion of Advanced PC Patients
News
Four in 10 adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations respond to treatment with Zejula (niraparib), according to early results of an ongoing Phase 2 trial. The GALAHAD study (NCT02854436), ... Read more